You just read:

Frost & Sullivan Publishes Update Coverage Report on RedHill Biopharma Ltd.: Net revenues for 2017 met expectations at $4M; likely capital raising in mid-2018 when Phase III results for Crohn's disease are announced; Price target raised to NIS 2.59

News provided by

Frost & Sullivan

Mar 14, 2018, 06:53 ET